IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy.
It is well established that both the production of IgE by B lymphocytes and the maturation and recruitment of eosinophils in late-phase reactions are dependent on the activation of allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient activation of allergen-specific T cells upon low-dose exposure to allergens is critically dependent on IgE-mediated or -facilitated allergen presentation. In fact, changes in the level of IgE-mediated allergen presentation may account for many of the immunological effects described for specific immunotherapy or anti-IgE treatment. This review aims to summarize the current knowledge, and will discuss the clinical relevance of blocking IgG antibodies induced by specific immunotherapy and anti-IgE monoclonal antibodies that both interfere with IgE-mediated allergen presentation.
van Neerven
R J J
RJ
Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands. jneerven@umcutrecht.nl
Knol
E F
EF
Ejrnaes
A
A
Würtzen
P A
PA
D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal; D017951:Antigen Presentation / Q000276:immunology*; D003888:Desensitization, Immunologic; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology* / Q000628:therapy; D007073:Immunoglobulin E / Q000276:immunology*; D007074:Immunoglobulin G; D008213:Lymphocyte Activation / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D000485:Allergens; D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007073:Immunoglobulin E